A second major trial has strengthened the case for using SGLT2 inhibitors in patients with heart failure and a reduced ejection fraction (HFrEF) regardless of diabetes status. Results seen with empagliflozin in the EMPEROR-Reduced trial show that those seen previously with dapagliflozin in the DAPA-HF were no fluke, according to cardiologists presenting findings at European ...
SGLT2 inhibitors now standard of care for heart failure: study
By Michael Woodhead
2 Sep 2020